Navigation Links
Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
Date:6/16/2009

WOODCLIFF LAKE, N.J., June 16 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that its development partner, BioAlliance Pharma, has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Loramyc(R) (miconazole Lauriad(R)) 50mg mucoadhesive buccal tablets, as planned. If approved, Strativa could launch Loramyc in the second half of 2010.

Loramyc (miconazole Lauriad(R)), an innovative antifungal therapy for the treatment of oropharyngeal candidiasis, was approved in the European Union in 2007 and is currently marketed in several EU territories.

About Strativa Pharmaceuticals

Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical, Inc. Strativa is committed to developing and marketing novel prescription drugs. Its initial focus is on supportive care therapeutics in HIV and oncology. Drawing on the specialty products expertise of its staff, Strativa possesses the resources to prepare products for commercialization and to help ensure their success after launch. For additional information, please visit www.strativapharma.com.

About Par Pharmaceutical

Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
2. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
3. CoreRx, Inc. Announces Plans for Expansions to Meet the Needs of Growing Pharmaceutical Formulation Development Business
4. New MedPredict Report Reveals Top Alzheimers Experts Insights on Diagnostics and Treatments in Development Pipeline
5. Jubilant to Work With Endo Pharmaceuticals on Drug Development
6. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
7. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
8. Plexus Awarded Development Contract With QIAGEN
9. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
10. Microbia, Inc. Names Alex Chu as Vice President of Process Development
11. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... (PRWEB) , ... January 20, 2017 , ... ... consulting and resource to the healthcare industry ( http://www.gandlscientific.com ), has announced the ... expanding team of clinical and scientific consultants and contractors. This is the latest ...
(Date:1/21/2017)... N.J. , Jan. 20, 2017 ... "Company"), a company that provides clinically useful molecular ... it has entered into a securities purchase agreement ... of 855,000 shares of common stock in a ... the Company has agreed to sell to the ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, today presented ... compound, napabucasin, at the 2017 American Society of Clinical ... Francisco . In a Phase ... agent designed to inhibit cancer stemness pathways by targeting ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo Bioworks, ... Gen9, a pioneer in the synthesis and assembly ... expertise in assembling pathway-length synthetic DNA into Ginkgo,s ... capacity in the construction of new organism designs ... "Gen9 was founded to significantly increase ...
Breaking Biology Technology:
(Date:1/13/2017)... N.Y. , Jan. 13, 2017 ... technology solutions for the homecare industry, including Electronic ... homecare industry expert, Justin Jugs, as Senior Vice ... more than 15 years of homecare experience to ... in developing strategic plans to align Sandata,s suite ...
(Date:1/12/2017)... 12, 2017 A new report by Allied Market Research, titled, ... biometric technology market is expected to generate revenue of $10.72 billion by 2022, with ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In the ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):